Prescient Therapeutics chooses three cancer programs for its next-generation CAR T platform
Melbourne-based Prescient will focus development of its OmniCAR platform into three programs: the blood cancer...
Melbourne-based Prescient will focus development of its OmniCAR platform into three programs: the blood cancer...
Prescient Therapeutics (PTX) has announced three internal development programs for its immune receptor technology platform,...
Following more than a decade of treatments, cancer survivor Laurie Adami now plans to tackle...
An American woman who owes her life to a bespoke cancer treatment is speaking out...
Laurie Adami has had a long and intricate journey with blood cancer, after being diagnosed...
In the battle against blood cancer, chimeric antigen receptor T cell (CAR-T) therapy is proving...
Special Report: A form of immunotherapy that involves modifying a patient’s white blood cells so...
Today, we will acquaint you with the product pipeline of ASX-listed clinical-stage biotechnology company Prescient Therapeutics...
StockTalk is a Stockhead video series featuring a roundtable of experts discussing a new investment topic each...

This investor centre was built by Reach Markets
©2025 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.